IGF-1 LR3

Overview

IGF-1 LR3 is a modified, longer-acting version of insulin-like growth factor 1 (IGF-1), a hormone naturally produced primarily by the liver in response to growth hormone stimulation. The "LR3" modification (Long Arg3) reduces its binding affinity to IGF-binding proteins, which extends its circulating half-life relative to native IGF-1.

Proposed Mechanism of Action

Like native IGF-1, LR3-IGF-1 activates the IGF-1 receptor, promoting cell growth, differentiation, and protein synthesis — of particular research interest in skeletal muscle, where IGF-1 signaling supports satellite cell proliferation and muscle protein synthesis. The LR3 modification's reduced binding-protein affinity means more of the administered dose is free to act on receptors, rather than being sequestered — the proposed basis for its increased potency relative to native IGF-1 at an equivalent dose.

Research Context

The cited study is worth reading carefully because its finding is more nuanced than "LR3-IGF-1 builds muscle." Rats were food-restricted at several severity levels and given continuous LR3-IGF-1 infusion; the peptide preserved overall body weight better than in untreated food-restricted animals, but did not specifically preserve skeletal muscle tissue — meaning the weight preservation likely came from other tissue compartments (e.g., fat or organ mass), not more or better-maintained muscle specifically.

Limitations of the Current Evidence

• The one study we verified here found LR3-IGF-1 did not selectively preserve skeletal muscle during food restriction — this directly complicates common claims that IGF-1 LR3 is a targeted muscle-building or muscle-preserving agent, at least under the conditions this study tested.
• This is a single animal study under a specific stress condition (food restriction); it doesn't address IGF-1 LR3's effects in normally-fed animals or in the exercise/hypertrophy context most commonly discussed in secondary sources.
• IGF-1 signaling is also implicated in cancer cell growth pathways in a substantial separate body of literature not covered by this citation — a consideration worth being aware of given IGF-1 LR3's extended half-life relative to native IGF-1.